Mental health in America is in a steady decline. About one-third of adults in the United States report symptoms of depression.1 This figure is 3x greater than in previous years. Depression is a mental health condition, but its impact goes far beyond mood and feelings.
People with depression are more likely to:
Researchers from Highmark, with support from the Richard King Mellon Foundation, conducted a two-year retrospective analysis on depression among our members. The team looked at how depression directly and indirectly impacts wellness and quality of life — emotionally, physically, and socially.
In particular, the study focused on the relationship between depression severity and health care utilization costs. Researchers received regulatory approvals from an Institutional Review Board, ensuring the study met all data privacy standards. Study results appeared in the Journal of Affective Disorders in September 2024.2
Approximately 745,000 members were identified as having some degree of depression during the study (2019 and 2020). About 369,000 of these members were included in the analysis for both years. This equates to 13.6 % of our 4+ million Highmark members diagnosed with depression in 2019 and 15.8 % in 2020.
Member data was gathered across Highmark’s home markets of Pennsylvania, West Virginia and Delaware, as well as from national markets.Researchers classified members by the severity of their depression symptoms: minimal, mild, moderate, severe, and unknown.
The team used the standard Patient Health Questionnaires (PHQ-2 and PHQ-9) to gauge depressive symptoms. PHQ-9 is a nine-item questionnaire for assessing depression severity, while PHQ-2 only uses the first two questions on PHQ-9. The PHQ-2 questions are
Researchers also used ICD-10 medical codes associated with depressive disorders that appeared in member insurance claims. Data on mood stabilizers, anti-anxiety medications, and anti-psychotics were also included when measuring depressive disorders.
Together with the PHQ assessments, this information told researchers that:
Highmark researchers uncovered significant cost implications associated with depressive disorders of varying severity. Key findings include:
Depression is projected to be a leading global health challenge by 2030, with an estimated cost of $300+ billion per year.3,4 That figure includes direct expenses for outpatient care, prescriptions, lab services, and hospitalization. There are also indirect costs associated with absenteeism, lower productivity, and poor quality of life.
All of this adds up to an increased total cost of care, especially when coupled with more expensive premiums and higher drug prices. Talk to your account manager about how Highmark can help your company alleviate depression among your staff. Highmark solutions minimize stigma around mental health care, while improving quality of life for our members
1 Ettman, C.K., Abdalla, S.M., Cohen, G.H., Sampson, L., Vivier, P.M., Galea, S., 2020. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw. Open 3, e2019686. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770146
2 Popkov, A.A., Barrett, T.S., Shergill, A., Donahue, M., Anderson, R.J., Karlin, B.E., 2024. Association between depression symptom severity and total cost of care: Findings from a large, 2-year, claims-based, retrospective population health study. https://www.sciencedirect.com/science/article/abs/pii/S0165032724015404?via%3Dihub
3 Mathers, C., Loncar, D., 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3, e442 https://doi.org/10.1371/journal.pmed.0030442
4 Greenberg, P.E., Fournier, A-A., Sisitsky, T., Simes, M., Berman, R., Koenigsberg, S.H., Kessler, R.C., 2021. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics 39, 653–665. doi: https://doi.org/10.1007/s40273-021-01019-4
Talk to your client manager today and we’ll help you find the right health plan for your company.